Pyrrolidine-1-carboximidamide hydrobromide

Catalog No.: 
ACQBWE621
CAS No.: 
175277-39-1
Molecular Formula: 
C5H12BrN3
Molecular Weight: 
194.08
Pyrrolidine-1-carboximidamide hydrobromide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$274.00InquiryInquiry
25g95%$1343.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NamePyrrolidine-1-carboximidamide hydrobromide
IUPAC Namepyrrolidine-1-carboximidamide hydrobromide
MDL No.MFCD00173788
Molecular FormulaC5H12BrN3
Molecular Weight194.08
SMILESN=C(N1CCCC1)N.[H]Br
InChI KeyNGHBTEAGXBELKR-UHFFFAOYSA-N
SynonymPYRROLIDINOFORMAMIDINE HYDROBROMIDE;PYRROLIDINE-1-CARBOXIMIDAMIDE HYDROBROMIDE;BUTTPARK 43\57-74;1-pyrrolidinecarboximidamide hydrochloride
CAS No.175277-39-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACQBWE621 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHFAI786 route compound structure diagram
    ACHFAI78629671-92-9In Stock
  2. Plus
  3. ACAHES352 route compound structure diagram
    ACAHES3526435-84-3In Stock
  4. Then
  5. ACQBWE621 route product structure diagram
    ACQBWE621175277-39-1
Inquiry

2. ACQBWE621 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQBWE621 route product structure diagram
    ACQBWE621175277-39-1
Inquiry

3. ACQBWE621 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQBWE621 route product structure diagram
    ACQBWE621175277-39-1
Inquiry

Comments (0)